Claims for Patent: 3,897,779

Summary for Patent: 3,897,779

Title:	Triamcinolone acetonide inhalation therapy
Abstract:	An aerosol container carrier and deceleration chamber for dispensing powdered triamcinolone acetonide with inhaled particles predominantly below 10 microns in size at a low velocity gives a comparatively high degree of topical effect in the lungs as compared with systemic effect from triamcinolone acetonide absorbed in the mouth or upper throat. The suspension of triamcinolone acetonide in dichlorodifluoromethane is preferably subjected to sonic waves at about -40.degree.C, resulting in a suspension having increased physical stability. A suspending agent such as anhydrous ethanol or sorbitan trioleate also increases stability.
Inventor(s):	Hansen; Lloyd Frank (Campbell Hall, NY)
Assignee:	American Cyanamid Company (Stamford, CT)
Application Number:	05/374,177
Patent Claims:	1. A method of treating asthma which comprises dispensing a measured dose through a metering valve into a deceleration chamber of a suspension in a chlorofluoroalkane propellant of finely divided triamcinolone acetonide having 95% by weight within the particle size range of about 0.5 to 10 microns, the individual particles of which are substantially separated, mixing with additional air, and inhaling, by inspirational air velocity only, into the lungs of the subject, holding the inspired air for a short time to permit a substantial portion of the particles of triamcinolone acetonide to be deposited along the lung surface, and exhaling.